Krystal Biotech Inc (KRYS)

Return on equity (ROE)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	57,161	10,932	-29,812	-140,409	-135,307	-139,975	-129,729	-115,468	-103,723	-69,570	-58,147	-52,168	-42,638	-32,167	-27,141	-21,803	-20,318	-19,088	-16,486	-14,490
Total stockholders’ equity	US$ in thousands	799,242	778,641	755,948	653,114	489,566	522,231	540,772	559,181	548,554	593,576	408,237	418,540	430,652	292,084	301,720	309,696	198,369	202,914	207,646	198,290
ROE		7.15%	1.40%	-3.94%	-21.50%	-27.64%	-26.80%	-23.99%	-20.65%	-18.91%	-11.72%	-14.24%	-12.46%	-9.90%	-11.01%	-9.00%	-7.04%	-10.24%	-9.41%	-7.94%	-7.31%

March 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $57,161K ÷ $799,242K
= 7.15%

Krystal Biotech Inc's return on equity (ROE) fluctuated over the past few quarters, showing both positive and negative values. The ROE was relatively low in the most recent quarter at 7.15%, indicating that the company generated a modest return for each unit of shareholder equity. Prior to that, the ROE had been negative for several quarters, reaching its lowest point at -27.64% in the first quarter of 2023.

The negative ROE figures suggest that Krystal Biotech Inc was not effectively utilizing its shareholders' equity to generate profits during those periods. This could be due to factors such as high levels of debt, poor operational efficiency, or declining profitability.

Overall, the trend in ROE for Krystal Biotech Inc indicates a need for the company to improve its financial performance and operational effectiveness to enhance shareholder value in the future. Additionally, investors and stakeholders may want to closely monitor the company's efforts to increase ROE and assess the impact of any strategic changes on its financial health.